NMRA
Neumora Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$396.85M
P/E Ratio
—
EPS
$-1.45
Beta
3.12
52W High
$3.65
52W Low
$0.61
50-Day MA
$2.71
200-Day MA
$2.07
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-235.95M |
| Operating Margin | 0.00% |
| Return on Equity | -121.20% |
| Return on Assets | -58.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.60 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $182.04M |
| Float | $104.56M |
| % Insiders | 24.25% |
| % Institutions | 56.24% |
Analyst Ratings
Consensus ($8.91 target)
2
Strong Buy5
Buy1
Hold1
Strong SellData last updated: 4/9/2026